DCIS Breast Cancer

17,421 views 62 slides Feb 08, 2014
Slide 1
Slide 1 of 62
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62

About This Presentation

Understanding and Treating DCIS (ductal carcinoma in situ) of the Breast


Slide Content

Ductal Carcinoma In Situ (Stage 0 Breast Cancer) Robert Miller MD www.aboutcancer.com

20% of breast cancers in the US are stage 0 or non-invasive (ducal carcinoma in situ DCIS or lobular carcinoma in situ LCIS)

Age Distribution For In Situ versus Invasive NCDB Data

Observed 5 Year Survival Breast Cancer 2003-2006 NCDB

What You Need to Know About Breast Cancer Before Deciding on Treatment Understand the basic anatomy (lobules, ducts and lymph nodes) Biopsy or pathology report tell you about the biology (how aggressive) of the cancer Breast imaging studies (mammograms or ultrasound) CT, MRI, PET Stage (particularly lymph node status )

Earliest form of cancer is often DCIS (ductal carcinoma in situ) then it progresses to invasive ductal carcinoma

ductal cells ductal carcinoma In situ (DCIS) Invasive ductal carcinoma

Normal duct cells inside a milk duct

Basement Membrane Normal Duct cells Cancer Cells DCIS Cancer cells are confined within the milk duct basement membrane so still in situ or non-invasive

Basement Membrane Normal Duct cells Cancer Cells Invasive Cancer Once the cells have invaded through the basement membrane and outside the duct it is called invasive or infiltrating

Pathology View of Ductal Carcinoma In Situ

Internal mammary supraclavicular axillary Lymph Nodes DCIS should not spread to the lymph nodes unless there is some invasion (may be focal micro-invasion) but 10 to 20 percent of lesions interpreted as DCIS on a core biopsy are upgraded to invasive cancer after excision

DCIS Wall of the duct DCIS Ductal Carcinoma In Situ

Understanding a Pathology Report Invasive or Not (DCIS, LCIS) Histology: what type of cancer Grade: fast or slow growing Hormone Receptors: is it sensitive to estrogen or progesterone HER2 (human epidermal growth factor receptor 2) a genetic mutation

Imaging The cells often die in place ( necrosis ) and then calcify. The radiologist is looking for abnormal areas of calcification

Mammograms often show areas of calcification, which can be benign or malignant Ninety percent of women with DCIS have microcalcifications on mammography and DCIS accounts for 80 percent of all breast cancers presenting with calcifications

Mammograms In ductal carcinoma in situ (DCIS), there is normally no mass but just an area of calcification (very small areas called microcalcifications)

Micro-calcifications can be very subtle Biopsy of this area showed 8mm DCIS

Biopsy = DCIS with focal micro-invasion

Larger area of micro-calcifications may have invasive cancer Path = 2.9 cm area of high grade DCIS plus invasive ductal cancer fat gland calcifications

Looking for advice on treatment decisions for ductal carcinoma in situ of the breast

Treatment Decisions with DCIS Surgery : total mastectomy versus conservation (lumpectomy ) and ? nodes Adjuvant Therapy : hormone therapy or as preventative strategy Radiation : whole breast or can it be skipped

Treatment Decisions The woman should be assisted by a multi-disciplinary team, including a surgeon, possibly a plastic surgeon, medical oncologist and a radiation oncologist

NCCN.org

Complete axillary lymph node resection should not be performed in the absence of evidence of invasive cancer or proven metastatic disease in women apparent pure DCIS . However, a small proportion of patients with apparent pure DCIS will be found to have invasive cancer at the time of their definitive surgical procedure. Therefore, the performance of a sentinel lymph node procedure should be strongly considered if the patient with apparent pure DCIS is to be treated with mastectomy or with excision in an anatomic location compromising the performance of a future sentinel node procedure.

Deciding on Surgery Lumpectomy Total Mastectomy The risk of cancer-related death in women with DCIS is low, estimated at 1.9 percent within 10 years. Mastectomy is curative for over 98 percent of patients with DCIS. Disease recurrence is rare after mastectomy (1 to 2 percent)

Breast Conservation Lumpectomy (remove the cancer with a small rim of normal tissue, clear margins) Sentinel node biopsy occasionally will be performed at the same time

At the time of the lumpectomy the surgeon tries to remove the cancer with a margin of normal breast tissue around the mass X-ray image of the lumpectomy specimen

Deciding on Radiation

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. Local Relapse in the Breast Over 15 Year Follow Up Lumpectomy Alone 19.4% Lump + Radiation 8.9 – 10% Lump + Radiation + Tamoxifen 7.3% Natl Cancer Inst. 2011;103(6):478. Survival was the same in all groups

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial JCO . 2013.49.5077

Cause specific survival Over all survival Years Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast.  JCO  Mar 1, 1996:754-63

Whole breast radiation following lumpectomy reduces the recurrence rates in DCIS by about 50%. Approximately half the recurrences are invasive and half are still DCIS . A number of factors determine the local recurrence risk: palpable mass, large size, higher grade, close or involved margins, and age < 50y. If the patient and physician view the individual risk as “low” some patients may be treated with excision alone. All data evaluating the three local treatments (lumpectomy alone, lumpectomy plus radiation or total mastectomy) show no difference in patient survival.

Van Nuys Index for Treatment of DCIS Score # 1 # 2 # 3 Path Other Comedo High Grade Size <15mm 16-40mm >40mm Margins >10mm 1-9mm < 1mm Score 3 – 4 : Lumpectomy alone (local control is 100% vs 97%) Score 5 – 7: Lumpectomy + Radiation (local control from 68% up to 85%) Score 8-9: Mastectomy Cancer  1996 Jun 1;77(11):2267-74 

Van Nuys Index for Treatment of DCIS Score # 1 # 2 # 3 Path Other Comedo High Grade Size <15mm 16-40mm >40mm Margins >10mm 1-9mm < 1mm Score 3 – 4 : Lumpectomy alone (local control is 100% vs 97%) Score 5 – 7: Lumpectomy + Radiation (local control from 68% up to 85%) Score 8-9: Mastectomy Cancer  1996 Jun 1;77(11):2267-74 

Updated Van Nuys Prognostic Index Parameter 1 Point 2 Points 3 Points Size <15mm 16-40mm >40mm Grade 1/II 1/II Necrosis III Margin 10mm 1-9mm <1mm Age >60 40-60 <40 4,5, 6 = Lumpectomy Alone 7, 8, 9 = Lumpectomy + Radiation 10, 11, 12 = Mastectomy 2003 Update PMID 14682107 -- "An argument against routine use of radiotherapy for ductal carcinoma in situ." (Silverstein MJ, Oncology (Williston Park). 2003 Nov;17(11):1511-33; discussion 1533-4, 1539, 1542 passim.) 

Online Breast Cancer Calculators http ://aboutcancer.com/breast_calculators.htm http://www.mskcc.org/cancer-care/adult/breast/prediction-tools

Deciding on Radiation

CT scan is obtained at the time of simulation CT images are then imported into the treatment planning computer. Note that at the time of the simulation the patient may receive 3 small tattoo marks

Computer generated anatomy images that will identify all the important structures to be sure the radiation covers the area of breast cancer and limits the dose to other areas

Viewed from the side, the radiation stops before hitting the lung

Typical technique for external beam

Radiation beam skims over the surface of the chest wall, ribs and lung

External Beam Radiation Monday through Friday for 5 weeks

After a lumpectomy the whole breast is radiated for about 5 weeks ( the red box ) and then a boost dose (5 – 7 treatments) is given to the lumpectomy site ( blue circle ) Radiation Fields

The whole breast treated 26 to 28 times The lumpectomy site is then treated 5 to 7 times

Generally the side effects of breast radiation do not become noticeable until the woman has received about 10 to 15 treatments, and then become somewhat more noticeable through the rest of the treatment. The most common side effects: skin irritation - the skin that is radiated gets red, itchy and may blister (like a sun burn) may lose hair in arm pit ( biafine , prutect , myaderm , aquaphor , silvadene , triamcinalone , Radiaderm ) breast or chest wall tenderness or mild pain tiredness or fatigue (some women feel a little light-headed) are swelling or edema Short Term Side Effects of Breast Radiation  

Long Term Side Effects of Breast Radiation Arm swelling or lymphedema is probably less than 3% Lung inflammation (pneumonitis) is 5% or less Risk of rib fracture is less than 3% Risk of nerve damage (brachial plexopathy ) < 1% Radiation fibrosis to breast Risk of causing a new cancer is less than 1%

DCIS BREAST CANCER Robert Miller MD www.aboutcancer.com